Caribou Biosciences, Inc. (CRBU) News
Filter CRBU News Items
CRBU News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CRBU News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CRBU News From Around the Web
Below are the latest news stories about CARIBOU BIOSCIENCES INC that investors may wish to consider to help them evaluate CRBU as an investment opportunity.
Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare ConferenceBERKELEY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, is scheduled to present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 am PST. For more information and a link to the live webcast, visit the Events page on Caribou’s website. |
Caribou Biosciences Appoints Sri Ryali as Chief Financial OfficerBERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as chief financial officer, effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in the biopharmaceutical industry to his role, and he will be responsible for the strategic leadership of the corporate finance, investor relations, and corporate communicat |
Why Is Caribou Biosciences Inc. (CRBU) Among the Top CRISPR Stocks to Invest In?We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Caribou Biosciences Inc. (NASDAQ:CRBU) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging […] |
Here's Why Caribou Biosciences (NASDAQ:CRBU) Must Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
Caribou Biosciences (CRBU) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowCaribou Biosciences (CRBU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
Caribou Biosciences to Participate in Upcoming Investor ConferencesBERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in the following investor conferences: Citi's 2024 Global Healthcare Conference, Miami, FL December 3, 2024, panel at 2:30 PM ESTPanel title: Cell therapies in autoimmune disordersWebcast 7th Annual Evercore ISI HealthCONx Confe |
Caribou Biosciences, Inc. (NASDAQ:CRBU) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next YearShareholders will be ecstatic, with their stake up 21% over the past week following Caribou Biosciences, Inc. 's... |
Caribou Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagCaribou Biosciences ( NASDAQ:CRBU ) Third Quarter 2024 Results Key Financial Results Revenue: US$2.02m (down 91% from... |
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue EstimatesCaribou Biosciences (CRBU) delivered earnings and revenue surprises of 13.64% and 39.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after prior CD19-targeted therapies) with HLA matching strategy in CB-010 ANTLER Phase 1 trial; next data report planned for H1 2025 -- -- Continuing dose escalation portion of the CB-011 CaMMouflage Phase 1 trial in r/r MM with higher lymphodepletion regimen following observations of efficacy; dose escalation d |